var data={"title":"Anakinra: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Anakinra: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5645?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=anakinra-drug-information\" class=\"drug drug_general\">see &quot;Anakinra: Drug information&quot;</a> and <a href=\"topic.htm?path=anakinra-patient-drug-information\" class=\"drug drug_patient\">see &quot;Anakinra: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135465\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kineret</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135466\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Kineret</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998315\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic, Disease Modifying</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Interleukin-1 Receptor Antagonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998342\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=anakinra-drug-information\" class=\"drug drug_general\">see &quot;Anakinra: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Familial Mediterranean Fever; colchicine-resistant:</b> Very limited data available: Children &ge;2 years and Adolescents: SubQ: 2 mg/kg/dose once daily; dose, frequency, and duration of therapy were adjusted as needed based on clinical response, usual reported duration: 4 to 8 months; some patients may require a longer duration. Patients continued to receive concomitant colchicine (Eroglu 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis (JIA):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Systemic-onset JIA (SOJIA): Children and Adolescents: SubQ: Initial: 1 to 2 mg/kg/dose once daily; maximum initial dose: 100 mg; if no response, may titrate typically at 2-week intervals by doubling dose up to 4 mg/kg/dose once daily; maximum dose: 200 mg (Dewitt 2012; Gattorno 2006; Hedrich 2012; Irigoyen 2006; Lequerr&eacute; 2008; Nigrovi 2011; Quartier 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Polyarticular course JIA: Children &ge;2 years and Adolescents: SubQ: 1 mg/kg once daily; maximum dose: 100 mg (Ilowite 2009; Reiff 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease, refractory to IVIG:</b> Very limited data available; reported dosing highly variable: Infants &gt;2 months and young children (eg, &lt;4 years): SubQ: 1 to 6 mg/kg/day in 1 to 2 divided doses; dosing based on case reports and expert recommendation as an alternate therapeutic option; a case report in a 2-year old reported a dose of 1 mg/kg/dose once daily; another case report in a 3-year old reported a dose of 2 mg/kg/dose once daily for 14 days; a higher dosing regimen was described in an 11-week old who had therapy initiated at 3 mg/kg/dose twice daily and further increased to 3 mg/kg/dose three times daily due to continued worsening clinical presentation; after clinical improvement and corticosteroid taper begun the anakinra dose was decreased to 4 mg/kg/dose twice daily (AHA [McCrindle 2017]; Cohen 2012; Sanchez-Manubens 2017; Shafferman 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neonatal-onset multisystem inflammatory disease (NOMID) or chronic infantile neurological, cutaneous, and articular syndrome (CINCA) [cryopyrin-associated periodic syndromes (CAPS)]:</b> Infants, Children, and Adolescents: SubQ: Initial: 1 to 2 mg/kg/day in 1 to 2 divided doses; adjust dose in 0.5 to 1 mg/kg increments as needed to control inflammation; usual maintenance dose: 3 to 4 mg/kg/day; maximum daily dose: 8 mg/kg/<b>day</b>. <b>Note:</b> Once-daily administration is preferred; however, the dose may also be divided and administered twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> Adolescents &ge;18 years: SubQ: 100 mg once daily; administer at approximately the same time each day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neonatal-onset multisystem inflammatory disease (NOMID) or chronic infantile neurological, cutaneous, and articular syndrome (CINCA) [cryopyrin-associated periodic syndromes (CAPS)]:</b> SubQ: Initial: 1 to 2 mg/kg daily in 1 to 2 divided doses; adjust dose in 0.5 to 1 mg/kg increments as needed; usual maintenance dose: 3 to 4 mg/kg daily; once-daily administration is preferred; however the dose may also be divided and administered twice daily; maximum daily dose: 8 mg/kg/<b>day</b>. <b>Note:</b> The prefilled syringe does not allow doses lower than 20 mg to be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> SubQ: 100 mg once daily; administer at approximately the same time each day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>NOMID:</i> Infants, Children, Adolescents, and Adults: Decrease frequency of administration to every other day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Rheumatoid arthritis:</i> Adolescents &ge;18 years and Adults: Consider 100 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD: &lt;2.5% of the dose is removed by hemodialysis or CAPD:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>NOMID:</i> Infants, Children, Adolescents, and Adults: Decrease frequency of administration to every other day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Rheumatoid arthritis:</i> Adolescents &ge;18 years and Adults: 100 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135448\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kineret: 100 mg/0.67 mL (0.67 mL) [contains disodium edta, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135434\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998346\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Rotate injection sites; inject into outer area of upper arms, abdomen (do not use within 2 inches of belly button), front of middle thighs, or upper outer buttocks; injection should be given at least 1 inch away from previous injection site; do not administer into tender, swollen, bruised, red, or hard skin or skin with scars or stretch marks. Allow solution to warm to room temperature prior to use (30 minutes). Do not shake. Provided in single-use, preservative-free syringes with 27-gauge needles; discard any unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135463\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not shake. Protect from light. Discard any unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998316\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurological cutaneous and articular syndrome (CINCA), which is a cryopyrin-associated periodic syndrome (CAPS) [FDA approved in pediatric patients (age not specified) and adults]; treatment of moderately to severely active rheumatoid arthritis in patients who have failed one or more disease-modifying antirheumatic drugs (DMARDs); may be used alone or in combination with DMARDs that are not tumor necrosis factor (TNF)-blocking agents (eg, etanercept, adalimumab) (FDA approved in ages &ge;18 years and adults); has also been used for reducing signs and symptoms of systemic juvenile idiopathic arthritic (SJIA) and polyarticular-course juvenile idiopathic arthritis (JIA); management of patients with Kawasaki disease refractory to intravenous immunoglobulin (IVIG); treatment of Familial Mediterranean Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135491\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anakinra may be confused with amikacin, Ampyra</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kineret may be confused with Amikin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135489\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (NOMID)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypercholesterolemia (RA)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (RA), nausea (RA), vomiting (NOMID)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Change in platelet count (RA; decreased), decreased white blood cell count (RA), eosinophilia (RA)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (more common in RA; no correlation of antibody development and adverse effects)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (more common in RA; including cellulitis, pneumonia, and bone and joint infections)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (RA and NOMID)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (NOMID)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis (NOMID), upper respiratory tract infection (NOMID)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hepatitis (noninfectious), hypersensitivity reaction (including anaphylaxis, angioedema, pruritus, skin rash, urticaria), increased serum transaminases, metastases (malignant lymphoma, malignant melanoma), opportunistic infection, thrombocytopenia (including severe)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135453\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to <i>E. coli</i>-derived proteins, anakinra, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135438\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported; discontinue use if severe hypersensitivity occurs; medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Associated with an increased risk of serious infections in rheumatoid arthritis studies. Anakinra should not be initiated in patients with an active infection. If a patient receiving anakinra for rheumatoid arthritis develops a serious infection, therapy should be discontinued; if a patient receiving anakinra for neonatal-onset multisystem inflammatory disease (NOMID) develops a serious infection, the risk of a NOMID flare should be weighed against the risks associated with continued treatment. Safety and efficacy have not been evaluated in immunosuppressed patients or patients with chronic infections; the impact on active or chronic infections has not been determined. Immunosuppressive therapy (including anakinra) may lead to reactivation of latent tuberculosis or other atypical or opportunistic infections; test patients for latent TB prior to initiation, and treat latent TB infection prior to use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site reactions: Injection site reactions commonly occur (within first 4 weeks of therapy) and are generally mild with a duration of 14 to 28 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: May affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenia: A decrease in neutrophil count may occur during treatment. Assess neutrophil count at baseline, monthly for 3 months, then every 3 months for up to 1 year. In a limited number of patients with NOMID, neutropenia resolved over time with continued anakinra administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use with caution in patients with asthma; may have increased risk of serious infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment; extended dosing intervals (every other day) are recommended for severe renal insufficiency (CrCl &lt;30 mL/minute) and ESRD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use caution due to the potential higher risk for infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There is no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48838122\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and &ge;5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298752\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135442\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13251&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anakinra may enhance the adverse/toxic effect of Abatacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Interleukin-1 Receptor Antagonist may enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anakinra may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135444\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135456\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Information related to the use of anakinra during pregnancy is limited (Makol 2011; Ostensen 2011). Specific guidelines for use in pregnancy are not available (Saag [ACR] 2008); use should not be continued during pregnancy until more data is available (Makol 2011; Ostensen 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to anakinra during pregnancy may contact the Organization of Teratology Information Services (OTIS), Rheumatoid Arthritis and Pregnancy Study at 1-877-311-8972. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998348\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor improvement of symptoms and physical function assessments. Latent TB screenings prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential (baseline, then monthly for 3 months, then every 3 months for a period up to 1 year); serum creatinine; LFTs at baseline; HBV screening prior to initiating (HBV carriers should also be screened during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss); periodic skin examination</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Juvenile idiopathic arthritis:</b> Additional monitoring: CBC with differential and platelets, C-reactive protein, ESR, ferritin, and LDH [baseline, at follow-up visits (1 to 2 weeks; 1, 2, 6, and 9 months)] and with any treatment change (DeWitt 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135437\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antagonist of the interleukin-1 (IL-1) receptor. Endogenous IL-1 is induced by inflammatory stimuli and mediates a variety of immunological responses, including degradation of cartilage (loss of proteoglycans) and stimulation of bone resorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135452\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 4 to 6 hours; Severe renal impairment (CrCl &lt;30 mL/minute): ~7 hours; ESRD: 9.7 hours (Yang 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: SubQ: 3 to 7 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998354\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Anakinra is produced by recombinant DNA/<i>E. coli</i> technology. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135455\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Kineret Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/0.67 mL (0.67 mL): $167.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135458\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kineret (AT, AU, BB, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IL, IS, IT, KR, LT, LV, MT, NL, NO, PL, PT, RO, SE, SG, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Buescher ES, Malinowska I. Soluble receptors and cytokine antagonists in human milk. <i>Pediatr Res</i>. 1996;40(6):839-844.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/8947960 /pubmed\" target=\"_blank\" id=\"8947960 \">8947960 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Callejas JL, Oliver J, Mart&iacute;n J, et al, &quot;Anakinra in Mutation-Negative CINCA Syndrome,&quot; <i>Clin Rheumatol</i>, 2007, 26(4):576-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/16440135/pubmed\" target=\"_blank\" id=\"16440135\">16440135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen S, Tacke CE, Straver B, Meijer N, Kuipers IM, Kuijpers TW. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. <i>Ann Rheum Dis</i>. 2012;71(12):2059-2061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/22689319/pubmed\" target=\"_blank\" id=\"22689319\">22689319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/27432853/pubmed\" target=\"_blank\" id=\"27432853\">27432853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dewitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/22290637/pubmed\" target=\"_blank\" id=\"22290637\">22290637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eroglu FK, Be&#351;ba&#351; N, Topaloglu R, Ozen S. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. <i>Rheumatol Int</i>. 2015;35(10):1733-1737.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/26001859/pubmed\" target=\"_blank\" id=\"26001859\">26001859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gattorno M, Piccini A, Lasigli&egrave; D, et al, &quot;The Pattern of Response to Anti-Interleukin-1 Treatment Distinguishes Two Subsets of Patients With Systemic-Onset Juvenile Idiopathic Arthritis,&quot; <i>Arthritis Rheum</i>, 2008, 58(5):1505-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/18438814/pubmed\" target=\"_blank\" id=\"18438814\">18438814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldbach-Mansky R, Dailey NJ, Canna SW, et al, &quot;Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1Beta Inhibition,&quot; <i>N Engl J Med</i>, 2006, 355(6):581-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/16899778/pubmed\" target=\"_blank\" id=\"16899778\">16899778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hedrich CM, Bruck N, Fiebig B, Gahr M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).<i> Rheumatol Int</i>. 2012;32(11):3525-3530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/22083619/pubmed\" target=\"_blank\" id=\"22083619\">22083619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilowite N, Porras O, Reiff A, et al, &quot;Anakinra in the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis: Safety and Preliminary Efficacy Results of a Randomized Multicenter Study,&quot; <i>Clin Rheumatol</i>, 2009, 28(2):129-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/18766426/pubmed\" target=\"_blank\" id=\"18766426\">18766426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Irigoyen P, Olson J, Horn C, et al, &quot;Treatement of Systemic Onset Juvenile Idiopathic Arthritis With Anakinra,&quot; <i>Ped Rheumatol Online J</i>, 2006, 4(2):123-34</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kashiwagi Y, Kawashima H, Nishimata S, et al, &quot;Extreme Efficiency of Anti-Interleukin 1 Agent (Anakinra) in a Japanese Case of CINCA Syndrome,&quot; <i>Clin Rheumatol</i>, 2008, 27(2):277-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/17891446/pubmed\" target=\"_blank\" id=\"17891446\">17891446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kineret (anakinra) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lequerr&eacute; T, Quartier P, Rosellini D, et al, &quot;Interleukin-1 Receptor Antagonist (Anakinra) Treatment in Patients With Systemic-Onset Juvenile Idiopathic Arthritis or Adult Onset Still Disease: Preliminary Experience in France,&quot; <i>Ann Rheum Dis</i>, 2008, 67(3):302-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/17947302/pubmed\" target=\"_blank\" id=\"17947302\">17947302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovell DJ, Bowyer SL, and Solinger AM, &quot;Interleukin-1 Blockade by Anakinra Improves Clinical Symptoms in Patients With Neonatal-Onset Multisystem Inflammatory Disease,&quot; <i>Arthritis Rheum</i>, 2005, 52(4):1283-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/15818707/pubmed\" target=\"_blank\" id=\"15818707\">15818707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. <i>Drugs</i>. 2011;71(15):1973-1987.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/21985166 /pubmed\" target=\"_blank\" id=\"21985166 \">21985166 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsubayashi T, Sugiura H, Arai T, et al, &quot;Anakinra Therapy for CINCA Syndrome With a Novel Mutation in Exon 4 of the CIAS1 Gene,&quot; <i>Acta Paediatr</i>, 2006, 95(2):246-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/16449034/pubmed\" target=\"_blank\" id=\"16449034\">16449034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term mManagement of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. <i>Arthritis and Rheumatism</i>. 2010;62(1): 258-267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/20039428/pubmed\" target=\"_blank\" id=\"20039428\">20039428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. <i>Arthritis Rheum</i>. 2011;63(2):545-555.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/21280009/pubmed\" target=\"_blank\" id=\"21280009\">21280009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohlsson V, Baildam E, Foster H, et al, &quot;Anakinra Treatment for Systemic Onset Juvenile Idiopathic Arthritis (SOJIA),&quot; <i>Rheumatology (Oxford)</i>, 2008, 47(4):555-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/18321945/pubmed\" target=\"_blank\" id=\"18321945\">18321945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ostensen M, F&ouml;rger F. Treatment with biologics of pregnant patients with rheumatic diseases. <i>Curr Opin Rheumatol</i>. 2011;23(3):293-298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/21346578 /pubmed\" target=\"_blank\" id=\"21346578 \">21346578 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pascual V, Allantaz F, Arce E, et al, &quot;Role of Interleukin-1 (IL-1) in the Pathogenesis of Systemic Onset Juvenile Idiopathic Arthritis and Clinical Response to IL-1 Blockade,&quot; <i>J Exp Med</i>, 2005, 201(9):1479-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/15851489/pubmed\" target=\"_blank\" id=\"15851489\">15851489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). <i>Ann Rheum Dis</i>. 2011;70(5):747-754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/21173013/pubmed\" target=\"_blank\" id=\"21173013\">21173013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiff A, &quot;The Use of Anakinra in Juvenile Arthritis,&quot; <i>Curr Rheumatol Rep</i>, 2005, 7(6):434-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/16303102/pubmed\" target=\"_blank\" id=\"16303102\">16303102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rigante D, Ansuini V, Caldarelli M, et al, &quot;Hydrocephalus in CINCA Syndrome Treated With Anakinra,&quot; <i>Childs Nerv Syst</i>, 2006, 22(4):334-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/16525848/pubmed\" target=\"_blank\" id=\"16525848\">16525848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis Rheum</i>. 2008;59(6):762-784.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/18512708 /pubmed\" target=\"_blank\" id=\"18512708 \">18512708 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&aacute;nchez-Manubens J, Gelman A, Franch N, et al. A child with resistant Kawasaki disease successfully treated with anakinra: a case report. <i>BMC Pediatr</i>. 2017;17(1):102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/28390409/pubmed\" target=\"_blank\" id=\"28390409\">28390409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. <i>Pediatr Rheumatol Online J</i>. 2014;12:26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/25045337/pubmed\" target=\"_blank\" id=\"25045337\">25045337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang BB, Baughman S, and Sullivan JT, &quot;Pharmacokinetics of Anakinra in Subjects With Different Levels of Renal Function,&quot; <i>Clin Pharmacol Ther</i>, 2003, 74(1):85-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-pediatric-drug-information/abstract-text/12844139/pubmed\" target=\"_blank\" id=\"12844139\">12844139</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13251 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135465\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135466\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F998315\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F998342\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135448\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F135434\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F998346\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F135463\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F998316\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F135491\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135489\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135453\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135438\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F48838122\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298752\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135442\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135444\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135456\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F998348\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135437\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F135452\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F998354\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F135455\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135458\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13251|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=anakinra-drug-information\" class=\"drug drug_general\">Anakinra: Drug information</a></li><li><a href=\"topic.htm?path=anakinra-patient-drug-information\" class=\"drug drug_patient\">Anakinra: Patient drug information</a></li></ul></div></div>","javascript":null}